Correction to "If you cannot measure it, you cannot improve it". Outcome measures in Duchenne muscular dystrophy: current and future perspectives.
作者信息
Benemei Silvia, Gatto Francesca, Boni Luca, Pane Marika
机构信息
Medical Affairs, Pfizer Italy, Rome, Italy.
U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
出版信息
Acta Neurol Belg. 2024 Oct;124(5):1763. doi: 10.1007/s13760-024-02619-5.
Abstract
摘要
相似文献
1
Correction to "If you cannot measure it, you cannot improve it". Outcome measures in Duchenne muscular dystrophy: current and future perspectives.对“如果你无法衡量它，你就无法改进它”的修正。杜氏肌营养不良症的结局指标：现状与未来展望
Acta Neurol Belg. 2024 Oct;124(5):1763. doi: 10.1007/s13760-024-02619-5.
2
"If you cannot measure it, you cannot improve it". Outcome measures in Duchenne Muscular Dystrophy: current and future perspectives.“如果你无法衡量它，你就无法改进它”。杜氏肌营养不良症的结果指标：现状与未来展望。
Acta Neurol Belg. 2025 Feb;125(1):1-12. doi: 10.1007/s13760-024-02600-2. Epub 2024 Jul 31.
3
'It is easier to not allow them to see your disability straight away, to see you as a person': An Interpretative Phenomenological Analysis of video gaming from the perspectives of men with Duchenne Muscular Dystrophy.“最好一开始就不让他们直接看到你的残疾，而将你视为一个普通人”：从杜氏肌营养不良症男性患者的角度出发，对视频游戏的阐释现象学分析。
Palliat Med. 2023 Jul;37(7):1016-1024. doi: 10.1177/02692163231172246. Epub 2023 May 2.
4
Glucocorticoid corticosteroids for Duchenne muscular dystrophy.用于杜氏肌营养不良症的糖皮质激素皮质类固醇
Cochrane Database Syst Rev. 2008 Jan 23(1):CD003725. doi: 10.1002/14651858.CD003725.pub3.
5
Glucocorticoid corticosteroids for Duchenne muscular dystrophy.用于杜氏肌营养不良症的糖皮质激素皮质类固醇
Cochrane Database Syst Rev. 2004(2):CD003725. doi: 10.1002/14651858.CD003725.pub2.
6
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.他莫昔芬治疗杜氏肌营养不良症男孩的安全性和有效性（TAMDMD）：一项多中心、随机、双盲、安慰剂对照的 3 期临床试验。
Lancet Neurol. 2023 Oct;22(10):890-899. doi: 10.1016/S1474-4422(23)00285-5.
7
Rasch analysis of the 32-item motor function measure in ambulant patients with Duchenne muscular dystrophy.对杜兴氏肌营养不良症能行走患者的32项运动功能测量指标进行拉施分析。
Clin Rehabil. 2023 Apr;37(4):569-582. doi: 10.1177/02692155221135843. Epub 2022 Oct 26.
8
Current Challenges of Using Patient-Level Claims and Electronic Health Record Data for the Longitudinal Evaluation of Duchenne Muscular Dystrophy Outcomes.使用患者级别的索赔和电子健康记录数据对杜氏肌营养不良症结果进行纵向评估所面临的当前挑战。
Adv Ther. 2024 Sep;41(9):3615-3632. doi: 10.1007/s12325-024-02897-8. Epub 2024 Jul 30.
9
[EPIDEMIOLGY OF DUCHENNE MUSCULAR DYSTROPHY IN THE RUSSIAN FEDERATION].[俄罗斯联邦杜氏肌营养不良症的流行病学]
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2024 Oct;32(Special Issue 2):1170-1175. doi: 10.32687/0869-866X-2024-32-s2-1170-1175.
10
Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.靶向外显子跳跃作为杜氏肌营养不良症的一种潜在基因校正疗法。
Neuromuscul Disord. 2002 Oct;12 Suppl 1:S71-7. doi: 10.1016/s0960-8966(02)00086-x.
引用本文的文献
1
Imu-based kinematic analysis to enhance upper limb motor function assessment in neuromuscular diseases.基于惯性测量单元的运动学分析，以加强对神经肌肉疾病上肢运动功能的评估。
J Neuroeng Rehabil. 2025 Mar 18;22(1):63. doi: 10.1186/s12984-025-01602-2.
Zotero 插件